Literature DB >> 27506741

The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.

Pingping Yang1, Tianlun Huang2, Gaosi Xu3.   

Abstract

Entities:  

Keywords:  Diabetic kidney disease; Endothelin; Finerenone; Mineralocorticoid receptor antagonists

Mesh：

Substances：

Year:  2016        PMID： 27506741     DOI： 10.1016/j.metabol.2016.06.001

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  2 in total

Review 1.  Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.

Authors:  Hermann Haller
Journal:  Herz       Date:  2022-09-12       Impact factor: 1.740

Review 2.  SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.

Authors:  Honghong Zou; Baoqin Zhou; Gaosi Xu
Journal:  Cardiovasc Diabetol       Date:  2017-05-16       Impact factor: 9.951
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.